Mirror photo by Patrick Waksmunski / Johnathan Dodson, an intensive care unit nurse practitioner who treats COVID-19 patients at UPMC Altoona, recently met the woman who donated the stem cells that helped him overcome leukemia.

A few weeks ago, nurse practitioner and former leukemia patient Johnathan Dodson interrupted a reporters phone interview to give his two young sons a hug and a kiss before they went to sleep.

The interview concerned the Claysburg natives recent appearance as a healthcare hero on Jimmy Kimmel Live, because Dodson treats COVID-19 patients at UPMC Altoona.

The segment also featured Dodsons surprise virtual meeting on the show with his own healthcare hero: the Texas woman who donated the stem cells that enabled Dodson to survive past his early 20s via a transplant.

Theyre here because of her, Dodson, 36, said of the little boys hed just sent off to bed.

In the interaction that followed the on-screen introduction to his donor, Dodson tried to explain his feelings about what the woman had done: how it hadnt been limited to saving his life, but had also kept his parents, siblings and friends from losing him and had spread out to allow for the establishment of his own family, including those kids, Chase, now 7, and Karter, now 4.

I dont think she realized the ripple effects, Dodson said.

He had long thought about a first encounter with Shannon Weishuhn of Rowlett, Texas.

I had kind of prepared this thank-you speech in my head, he said.

(But) how do you thank someone who saved your life? Dodson asked.

For Weishuhn, also a nurse, the donation was an ancient memory, Dodson said, based on an off-screen conversation he had with her, which included a virtual meeting with his family.

She had no idea of the butterfly effect that her action had on his world, he said, speaking of the idea that small occurrences can have big consequences. Thats the message I was trying to convey, he said.

Almost didnt make it

Dodson almost didnt make it to the transplant.

But in the process of getting through his difficulties with leukemia, he found his calling.

He was diagnosed initially in 2003.

He went through chemotherapy to wipe out my immune system, which also wiped out the cancer cells, he said.

The idea was to do an immune system reset, with the hope that the cancer cells wouldnt grow back, he said.

He went into remission, but relapsed at the beginning of 2004, he said.

So he underwent chemotherapy again.

He relapsed again.

The third time he got chemo was in preparation for the transplant.

He nearly died multiple times, and at one point, his survival chances shrunk to about 3 percent, Dodson said.

The cancer had broken into his spine and his brain, he said.

Only a handful of prior cases had been treated successfully when that had happened, he said.

There were three options a shunt in his head and more chemotherapy, spinal taps with chemo or hospice at home, he said.

His parents knew he didnt want a shunt in his head, so that was out of the question, Dodson said.

His parents asked the doctors what theyd do if he was their son, and they recommended hospice, he said.

But a nurse stepped in and said you need to give him a chance, arguing that his survival from two previous crises should merit another try, Dodson said.

Thats when my parents switched and opted for treatment, Dodson said. That sealed the deal.

Once the decision was made, there was talk about sending him to Texas, the only place where the contemplated treatment had been done successfully, he said.

Dodson nixed that.

If I was going to die, I was going to die here, he said.

The reason Im here today

By that time, the nurses who took care of him at West Penn Hospital, now part of Allegheny Health Network, had almost become family, he said.

They along with his donor are the reason Im here today, he said.

The nurses are also the reason hes a nurse himself.

The transplant, however, didnt suddenly make things all better.

He had a really rough go (afterwards), said Dr. John Lister, chief of the division of hematology and cellular therapy of Allegheny Health Network Cancer Institute and a member of Dodsons transplant team.

Caring for patients after leukemia transplants is as challenging as anything in medicine, said Lister, who is a descendant of Joseph Lister, a pioneer in antiseptic surgery.

Its challenging because the blood stem cells harvested from the donors blood, when injected into the recipient, create a new white-blood-cell immune system that attacks the recipients diseased white-blood-cell immune system, Lister indicated.

It can be fatal, he said. And extremely debilitating.

Doctors deal with it by giving powerful immunosuppressant medications, he said.

The direction of attack the donor material attacking the recipients is the opposite of the direction of attack with transplants of organs like kidneys, Lister said.

After those other transplants, the recipients immune system attacks the donor organ, he said.

Dodson was kept alive due to the intensive efforts of many people, Lister said.

Eventually, the initial reaction dies down, Lister said.

Hes totally normal at this point, Lister said of Dodson. I would say hes cured.

The donor matched Dodson in certain key genes that make the immune system work, Lister said.

The harvesting of donor stem cells occurs after the donor is given a growth factor that causes those stem cells to leave the bone marrow and enter the bloodstream, Lister said.

Blood stem cells can become any of the three types of blood cells, given the right conditions.

When injected into the recipient, they home to the marrow where theyre needed, according to Lister.

There they divide and repopulate, he said.

Anyone willing to make a bone marrow or stem cell donation can go to bethematch.org.

Its free to register, Dodson said. More ethnically diverse donors are needed, he added.

Last year, the web site helped facilitate 6,425 transplants, Dodson said.

You could change someones life forever, he said.

Today's breaking news and more in your inbox

Continued here:
UPMC nurse practitioner hailed 'healthcare hero' on live TV - Altoona Mirror

Bone Marrow Stem Cells Comments Off on UPMC nurse practitioner hailed ‘healthcare hero’ on live TV – Altoona Mirror | October 29th, 2020

Catalent Biologics has agreed to manufactureNurOwn, the cell-based therapy by BrainStorm Cell Therapeuticsbeing evaluated in a soon-to-conclude pivotal trial as a possible treatment of amyotrophic lateral sclerosis (ALS).

With this agreement, Catalent will produce NurOwn under current Good Manufacturing Practices standards set to ensure that batches of a medicine are produced with consistent high quality at its new 32,000-square-foot cell therapy manufacturing facility in Houston.

We are proud to have a partner in Catalent whose excellence in manufacturing quality therapies will support commercial supply of NurOwn, Chaim Lebovits, BrainStorms CEO, said in a press release.

With NurOwn, a patients mesenchymal stem cellsare collected from the bone marrow and treated in the lab to produce proteins called neurotrophic factors (NTFs), compounds that promote nervous tissue growth and survival. (Mesenchymal stem cells, orMSCs, are stem cells that can differentiate into a variety of other cell types.)

The modified cells called MSC-NTF cells are then injected into the patients spinal cord, where their NTFs are expected to promote the growth and survival of nerve cells, which are damaged over the course of ALS.

Using a patients own cells as a therapy minimizes the risk of an immune reaction, as might occur with cells from a donor.

The U.S. Food and Drug Administration has given NurOwn bothfast track and orphan drugdesignations to support and speed its development for ALS. The medicine also received orphan drug designation from the European Medicines Agency.

We know that ALS patients are in urgent need of a new treatment option. If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients, Lebovits added.

NurOwn showed an ability to slow progression in people with fast-progressing disease in a Phase 2 trial (NCT02017912). This led Brainstorm to open a Phase 3 trial (NCT03280056)to confirm those findings in a larger group of ALS patients.

The trial, taking place at six sites in the U.S., enrolled 200 patients and randomly assigned them to either NurOwn or a placebo, given in three intrathecal (into the spinal cord) injections at two-month intervals.

Researchers are evaluating NurOwns effectiveness using therevised amyotrophic lateral sclerosis functional rating scale(ALSFRS-R), which assesses such daily life abilities as swallowing, speaking, dressing and washing oneself, climbing stairs, and turning over in bed.

Its primary goal is to determine whether NurOwn outperforms a placebo at reducing the rate of decline in ALSFRS-R scores over six months. A change of 1.25 points or more in ALSFRS-R scores each month, compared to scores recorded prior to treatment, defines a responder.

Other trial goals include safety, the number of patients whose disease has not progressed, total ALSFRS-R decline, and overall survival. Samples of blood and cerebrospinal fluid will also be collected to evaluate biomarkers, like neurotrophic factors and immune molecules, in response to the treatment.

BrainStorm expects to deliver top-line results this year; the study is set to fully conclude in December.

Should results be positive and NurOwn be approved for clinical use, BrainStorm and Catalent will consider extending their partnership to allow for commercial manufacturing of NurOwn at the Houston facility.

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

Total Posts: 45

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

See more here:
Catalent to Produce BrainStorm's NurOwn Cell Therapy for ALS - ALS News Today

Bone Marrow Stem Cells Comments Off on Catalent to Produce BrainStorm’s NurOwn Cell Therapy for ALS – ALS News Today | October 29th, 2020

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.

City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001. The cancer center will leverage both patient samples from the ongoing NexImmune Phase 1/2 clinical study of NEXI-001 in acute myeloid leukemia (AML) patients with relapsed disease after allogeneic stem cell transplantation and the centers tumor repository bank of primary leukemia samples, one of the largest collections in the world, to drive the research.

NEXI-001 is a cellular product candidate that contains populations of naturally occurring CD8+ T cells directed against multiple antigen targets for AML, and it is the first clinical product generated by the Companys AIM nanoparticle technology.

NexImmune has developed a unique and versatile technology platform that lends itself very effectively to important areas of ongoing research in the field of AML, said Guido Marcucci, M.D., Chair and Professor with City of Hopes Department of Hematologic Malignancies Translational Science. Our collective goal is to translate future research findings into new, more effective T cell immunotherapies to the benefit of these very difficult to treat patients.

A key objective of the research will focus on the identification of new antigen targets that are expressed on both leukemic blasts as well as leukemic stem cells, and those which represent survival proteins to both. Once identified, these antigen targets will be loaded on NexImmune AIM-nanoparticles to expand antigen-specific CD8+ T cells, and evaluated in pre-clinical models for anti-tumor potency, tumor-specific killing, and response durability.

In addition, the research initiative will aim to further understand different mechanisms of tumor escape, such as tumor antigen and human leukocyte antigen (HLA) downregulation due to immune pressure.

Research between NexImmune and City of Hope will inform a scientific understanding of how the immune system can address certain tumor escape mechanisms to more effectively fight aggressive cancers like AML, and how this might be accomplished with NexImmunes AIM technology and T cell products, said Monzr Al Malki, M.D., Director of City of Hopes Unrelated Donor BMT Program and Haploidentical Transplant Program and an Associate Clinical Professor with Department of Hematology and Hematopoietic Cell Transplantation. Based on our current clinical experience with this technology, were excited to learn what more this research will tell us.

City of Hope is a world-class clinical research institution that has built one of the largest banks of leukemia samples in the world, said Han Myint, M.D., NexImmune Chief Medical Officer. The depth of expertise that Drs. Marcucci, Al Malki and their team bring to this research initiative will help NexImmune continue to develop innovative products that can help patients with AML and other hard-to-treat cancers.

City of Hope is a leader inbone marrow transplantation. More than 16,000 stem cell and bone marrow transplants have been performed at City of Hope, and more than 700 are performed annually. City of Hopes BMT program is the only one in the nation that has had one-year survival above the expected rate for 15 consecutive years, based on analysis by the Center for International Blood and Marrow Transplant Research.

About NexImmuneNexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM technology is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic cancers. AIM nanoparticles (AIM-np) act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties as characterized by in vitro analysis, including a unique combination of anti-tumor potency, antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas, with both cell therapy and injectable products.

NexImmunes two lead T cell therapy programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy, respectively. The Companys pipeline also has additional preclinical programs, including cell therapy and injectable product candidates, for the treatment of oncology, autoimmune disorders, and infectious diseases.

For more information, visit http://www.neximmune.com.

Media Contact:Mike BeyerSam Brown Inc. Healthcare Communications312-961-2502mikebeyer@sambrown.com

Investor Contact:Chad RubinSolebury Trout+1-646-378-2947crubin@soleburytrout.com

More:
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia - GlobeNewswire

Bone Marrow Stem Cells Comments Off on NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia – GlobeNewswire | October 29th, 2020

What is Adipose Tissue Derived Stem Cell Therapy?

Adipose tissue derived stem cells (ADSCs) are stem cells originated from adipocytes. ADSCs have characteristics similar to bone marrow mesenchymal stem cells. Thus Adipose-derived stem cells substitute for bone marrow as a source of stem cells. Different varieties of manual and automatic stem cell separation procedures are used to separate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can be utilized to isolate ADSCs from other stem cells within a cell solution. Currently, adipose derived stem cells (ADSCs) are generally used in the generation of regenerative medicine due to its anti-inflammatory, anti-apoptotic, and immunomodulatory properties.

Download PDF Sample Report Here @ https://www.theinsightpartners.com/sample/TIPRE00014843/

The research provides answers to the following key questions:

A new market study report by The Insight Partners on the Adipose Tissue Derived Stem Cell Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets. Some of the key players in the study are AlloCure, Inc, Antria, Inc., Celgene Corporation, Cellleris SA, Corestem, Inc., Cytori Therapeutics, LLC, Intrexon, Inc., Mesoblast Ltd., Pluristem Therapeutics, Inc., Tissue Genesis, Inc. etc.

Market Insights:

The Adipose Tissue-derived Stem Cell Therapy Market is growing due to increasing use of regenerative medicine in disease treatment and increasing private and public funding for stem cell therapy. However, high cost associated with stem cell processing hampers growth of this market.

An Overview of the Impact of COVID-19 on this Market:

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Adipose Tissue Derived Stem Cell Therapy Market which would mention How the Covid-19 is Affecting the Adipose Tissue Derived Stem Cell Therapy Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Adipose Tissue Derived Stem Cell Therapy Players to fight Covid-19 Impact.

Adipose Tissue Derived Stem Cell Therapy Market: Regional analysis includes:

The Adipose Tissue Derived Stem Cell Therapy Market segments and Market Data Break Down are illuminated below:By Cell Type (Autologous Stem Cells, Allogeneic Stem Cells);

Product (Cell Line, Culture Media);

Disease (Cancer, Obesity, Wounds and Injuries, Musculoskeletal Diseases, Cardiovascular Diseases, Others);

End User (Hospitals and Trauma Centers, Cell banks and Tissue Banks, Research Laboratories and Academic Institutes, Others)

The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Adipose Tissue Derived Stem Cell Therapy market. Further, the report conducts an intricate examination of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal with regard to different segments. The report predicts the influence of different industry aspects on the Adipose Tissue Derived Stem Cell Therapy market segments and regions.

This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Adipose Tissue Derived Stem Cell Therapy market.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure @ https://www.theinsightpartners.com/buy/TIPRE00014843/

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 10+ companies.

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Visit link:
Adipose Tissue Derived Stem Cell Therapy Market to Set Phenomenal Growth in Key Regions by 2027 | AlloCure, Inc, Antria, Inc., Cellleris SA, Tissue...

Bone Marrow Stem Cells Comments Off on Adipose Tissue Derived Stem Cell Therapy Market to Set Phenomenal Growth in Key Regions by 2027 | AlloCure, Inc, Antria, Inc., Cellleris SA, Tissue… | October 29th, 2020

After tackling two major research challenges, the founders of Be Biopharma are ready to announce their official launch along with a $52 million funding round. They are intent upon usingthe bodys B cells to treat a range of diseases.

The Series A round was led by Atlas Venture and RA Capital Management. Joining in were Longwood, Alta Partners and Takeda Ventures.

We have an ambitious plan to be the company that knows how to make B cells and mirror them precisely and make them at scale, Aleks Radovic-Moreno, Be Biopharmas president and director, said in a phone interview.

B cells, which play a leading role in the bodys immune response, can be taken out, genetically programmed to help fight specific diseases and then put back in the body. The cells also can come from healthy donors.

The challenges involved being able to efficiently edit the cells and then make them in sufficient quantities, Radovic-Moreno said. Those are the two big problems we have overcome.

Founded this year, Be Biopharma is looking to hire people in research, engineering and manufacturing, as well as a full-time leadership team, said Radovic-Moreno, an entrepreneur in residence at Longwood Fund, a co-founder and investor in Be Biopharma. The startups CEO is David Steinberg, a general partner at Boston-based Longwood.

From there, the company hopes to begin developing therapeutics for use in people. Cancers and autoimmune diseases are potential targets, as are monogenic diseases like cystic fibrosis. B cells, for example, could replace the need for invasive bone marrow transplants, Radovic-Moreno said.

If we can do that, it would change the lives of so many people. So, were trying to move that as fast as humanly possible, said Radovic-Moreno, who declined to offer a specific timeline.

The path for B cells could be relatively quick, he said, based on the experience of T cells and stem cells, he said. B cell therapies, though, are expected to be safer and less toxic than those involving T cells.

Be Biopharma is drawing on research undertaken at the Seattle Childrens Research Institute by Dr. David Rawlings and Richard James. They are among the co-founders of the new company.

B cells play a key role in combatting diseases by catalyzing humoral immunity the arm of the immune system that manufactures large quantities of proteins to neutralize disease-causing pathogens and manipulate immune cell behavior, Rawlings, director of the Center for Immunity and Immunotherapies at the Seattle institute, said in a statement. Today, this powerful part of the immune system is only passively and/or indirectly addressed therapeutically. Our ambition is to advance the field by building a new class of engineered B cell medicines that will provide direct control over the power of humoral immunity and help transform the prognosis for patients who currently have limited treatment options.

Picture: Feodora Chiosea, Getty Images

The rest is here:
Startup focused on B-cell therapies launched with $52M in Series A - MedCity News

Bone Marrow Stem Cells Comments Off on Startup focused on B-cell therapies launched with $52M in Series A – MedCity News | October 29th, 2020

Final Tranche is Anchored by Iconic Consumer Packaged Goods Private Equity Firm, Cambridge Companies SPG

Go here to read the rest:
Better Choice Closes Third Tranche of Series F and Completes Equity Raise Totaling Cumulative $21.7M

Global News Feed Comments Off on Better Choice Closes Third Tranche of Series F and Completes Equity Raise Totaling Cumulative $21.7M | October 27th, 2020

See the original post:
RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows

Global News Feed Comments Off on RespireRx Pharmaceuticals Inc. Announces Appointment of Dr. James Cook and Dr. Jeffrey Witkin as Research Fellows | October 27th, 2020

Company continues meeting enrollment milestones across clinical trials amid the COVID-19 pandemic, putting patient safety first Company continues meeting enrollment milestones across clinical trials amid the COVID-19 pandemic, putting patient safety first

Read the rest here:
Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory...

Global News Feed Comments Off on Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory… | October 27th, 2020

Pompano Beach, Fl., Oct. 27, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced the launch of AEON™, the 6th and newest addition to the Company’s perinatal tissue allograft platform.

Go here to see the original:
BioStem Technologies, Inc. Announces Launch of AEON™

Global News Feed Comments Off on BioStem Technologies, Inc. Announces Launch of AEON™ | October 27th, 2020

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will be presenting a poster during the 29th European Academy of Dermatology and Venereology (EADV) Congress being held virtually October 28 – November 1, 2020. The presentation will be posted onto Akari’s website.

Go here to read the rest:
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress...

Global News Feed Comments Off on Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress… | October 27th, 2020

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, and Chief Scientific Officer, Dr. Kenneth Cundy, will participate on the panel titled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus” at the ROTH Capital COVID-19 Therapeutics in Development Event, being held virtually on October 28, 2020 at 7:30am PT. A live webcast of the presentation will be available for attendees who register at https://roth.zoom.us/webinar/register/WN_FF_LgnOeQmm7VsRye97DtQ.

Excerpt from:
CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

Global News Feed Comments Off on CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event | October 27th, 2020

GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX?CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix?M™ adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States (U.S.) Center for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) meeting.

Read this article:
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update

Global News Feed Comments Off on Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update | October 27th, 2020

Mechelen, Belgium; 27 October 2020, 16.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) unveils the Toledo target family as a series of salt-inducible kinase inhibitors. Toledo exhibits a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines. Today, Galapagos also presents new preclinical and healthy volunteer data, and details its broad program to discover and develop multiple series of Toledo compounds with different selectivity profiles, aimed at treating a broad range of autoimmune conditions with important unmet medical need.

Follow this link:
Galapagos’ R&D Roundtable showcases Toledo program

Global News Feed Comments Off on Galapagos’ R&D Roundtable showcases Toledo program | October 27th, 2020

California cannabis leader to host conference call on November 10, 2020 California cannabis leader to host conference call on November 10, 2020

Link:
Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results

Global News Feed Comments Off on Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results | October 27th, 2020

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders of the Company’s American Depositary Receipts (“ADRs”).

Read more:
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)

Global News Feed Comments Off on Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs) | October 27th, 2020

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

More here:
Sanofi: Information concerning the total number of voting rights and shares - September 2020

Global News Feed Comments Off on Sanofi: Information concerning the total number of voting rights and shares – September 2020 | October 27th, 2020

Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting

Read the rest here:
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed...

Global News Feed Comments Off on Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed… | October 27th, 2020

AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2020 financial results after market close on Tuesday, November 10, 2020. The company will host a conference call and webcast at 4:30 PM ET that day to discuss its third quarter financial results and provide an update on corporate activities. There will also be a question and answer session following the prepared remarks.

Read more:
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020

Global News Feed Comments Off on Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020 | October 27th, 2020

SAN FRANCISCO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020.

Link:
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020

Global News Feed Comments Off on Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020 | October 27th, 2020

SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial results after the financial markets close on Thursday November 12, 2020.

Read the original:
Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020

Global News Feed Comments Off on Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020 | October 27th, 2020